Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Spero Therapeutics Inc SPRO

Healthcare Biotechnology
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections with unmet need. Its lead product candidate, SPR720, is an oral antimicrobial agent in development for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease... see more

Recent & Breaking News (NDAQ:SPRO)

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 30, 2020

Spero Therapeutics to Present at the Evercore ISI HealthCONx Conference on December 3, 2020

GlobeNewswire November 30, 2020

Spero Therapeutics Announces Third Quarter 2020 Operating Results and Provides Business Update

GlobeNewswire November 5, 2020

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 3, 2020

Spero Therapeutics to Provide Business Update and Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020

GlobeNewswire October 29, 2020

Spero Therapeutics to Present Data for All Pipeline Programs at IDWeek 2020

GlobeNewswire October 16, 2020

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire September 30, 2020

Spero Therapeutics Hosting Key Opinion Leader Call on Oral Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections

GlobeNewswire September 24, 2020

Spero Therapeutics to Present at Investor Conferences in September

GlobeNewswire September 15, 2020

Spero Therapeutics Announces Pricing of Securities Offering

GlobeNewswire September 11, 2020

Spero Therapeutics Announces Proposed Public Offering

GlobeNewswire September 9, 2020

Spero Therapeutics Announces Positive Topline Results from its Phase 3 ADAPT-PO Clinical Trial of Oral Tebipenem HBr in Complicated Urinary Tract Infection and Acute Pyelonephritis

GlobeNewswire September 8, 2020

Spero Therapeutics Announces FDA Acceptance of IND Application for SPR720

GlobeNewswire August 31, 2020

Spero Therapeutics Announces Second Quarter 2020 Operating Results and Provides Business Update

GlobeNewswire August 6, 2020

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire July 31, 2020

Spero Therapeutics to Provide Business Update and Report Second Quarter 2020 Financial Results on Thursday, August 6, 2020

GlobeNewswire July 29, 2020

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire June 30, 2020

Spero Investor Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Spero Therapeutics, Inc. To Contact The Firm

Newsfile June 17, 2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spero Therapeutics, Inc. - SPRO

GlobeNewswire June 8, 2020

Spero Investor Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Spero Therapeutics, Inc. To Contact The Firm

Newsfile June 4, 2020